non-human primates

There are 179 papers on aging in non-human primates: 8 observational studies in people, 60 in animals, 5 in cells, 99 reviews. The newest story, Nov 3, 2026: “Protein loss disrupts nuclear structure in primate cells”.

Organism

179 papers study it52 findings

6 new papers in 30 daysSee all 179 papers on non-human primates

At a glance

Reviews describe longer lifespan and lower age-related disease incidence with caloric restriction in non-human primates. A study in aged monkeys reports that long-term vitamin C lowers biological age and improves neurological and metabolic function. Another study reports fewer senescent cells and age-related pathologies with low-dose GFD-CD3 under transaminase-guided monitoring.

52 findings in 34 papers from 2014 to 2026, 8 of them since July 2026

  • Humans8
  • Animals59
  • Model organisms1
  • Cells5
  • In silico6

Interventions

33

Caloric restriction

downage-related disease incidence1downcancer1uplifespan1downoxidative stress and ROS signaling1

4 studies
  1. Caloric restriction decreases oxidative stress and ROS signaling in non-human primates.

    “Two-month CR intervention led to the recovery of many antioxidative metabolites and reshaped the Cys redoxome.”

    Animalstwo-month

    Low-input redoxomics facilitates global identification of metabolic regulators of oxidative stress in the gut

    Signal transduction and targeted therapy

  2. Caloric restriction extends lifespan in non-human primates.

    “The health benefits of chronic caloric restriction (CR) resulting in lifespan extension are well established in many species and has been recently demonstrated also in non-human primates”

    Review

    Caloric restriction, longevity and aging: Recent contributions from human and non-human primate studies

    Progress in neuro-psychopharmacology & biological psychiatry

  3. Caloric restriction decreases age-related disease incidence in non-human primates.

    “In human and non-human primates, CR has beneficial effects on human longevity and reduces the incidence of age-related diseases”

    Review

    The effects of calorie restriction on aging: a brief review

    European review for medical and pharmacological sciences

  4. Caloric restriction lowers the risk of cancer in non-human primates (review of diverse studies).

    “dietary restriction (DR) has been shown to slow the incidence of age-associated cardiovascular disease, metabolic disease, cancer and brain ageing in non-human primates”

    Reviewreview of diverse studies

    Lifespan modulation in mice and the confounding effects of genetic background

    Journal of genetics and genomics = Yi chuan xue bao

More on Caloric restriction

Vitamin C

downACSL41downbiological age1downferro-aging signatures1downmotor neuron senescence1+1

3 studies
  1. Vitamin C decreases biological age in non-human primates.

    “Multi-omic aging clocks indicate the VC-mediated reversal of biological age”

    Animalsover 40 months

    Vitamin C inhibits ACSL4 to alleviate ferro-aging in primates

    Cell metabolism

  2. Vitamin C improves neurological and metabolic functions in non-human primates (long-term administration in aged monkeys).

    “improves neurological and metabolic functions”

    Animalslong-term administration in aged monkeysover 40 months

    Vitamin C inhibits ACSL4 to alleviate ferro-aging in primates

    Cell metabolism

  3. Vitamin C decreases ferro-aging signatures in non-human primates (long-term administration in aged monkeys).

    “Long-term VC administration in aged monkeys for over 40 months potently reduces ferro-aging signatures across tissues”

    Animalslong-term administration in aged monkeysmultiple tissuesover 40 months

    Vitamin C inhibits ACSL4 to alleviate ferro-aging in primates

    Cell metabolism

  4. Vitamin C inhibits ACSL4 in non-human primates (supraphysiological concentrations).

    “vitamin C (VC), traditionally viewed as a broad-spectrum antioxidant, has been proposed to interact with and inhibit ACSL4 activity at supraphysiological concentrations”

    Reviewsupraphysiological concentrations

    Vitamin C, ACSL4, and Ferro-Aging: Mechanistic Insights and Translational Perspectives from Primate Studies

    Aging and disease

  5. Vitamin C decreases motor neuron senescence in non-human primates (counteracting CHIT1-driven pro-senescent effect).

    “ascorbic acid, a geroprotective compound, counteracted the pro-senescent effect of CHIT1 and mitigated motor neuron senescence in aged monkeys”

    Animalscounteracting CHIT1-driven pro-senescent effectspinal cord

    CHIT1-positive microglia drive motor neuron ageing in the primate spinal cord

    Nature

More on Vitamin C

AAV-NEUROD1

upcognitive function1upglucose metabolism1downhippocampal atrophy1downinflammation1

1 study
  1. AAV-NEUROD1 improves glucose metabolism in NHP AD models with hippocampal hTau overexpression.

    “It also repairs vascular and BBB damage, restores CSF AD biomarker levels, improves hippocampal glucose metabolism, and enhances spatial working memory.”

    Animalsin NHP AD models with hippocampal hTau overexpressionhippocampus

    A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease-Like Non-Human Primate Model

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  2. AAV-NEUROD1 improves cognitive function in NHP AD models with hippocampal hTau overexpression.

    “It also repairs vascular and BBB damage, restores CSF AD biomarker levels, improves hippocampal glucose metabolism, and enhances spatial working memory.”

    Animalsin NHP AD models with hippocampal hTau overexpressionbrain

    A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease-Like Non-Human Primate Model

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  3. AAV-NEUROD1 decreases inflammation in NHP AD models with hippocampal hTau overexpression.

    “NeuroD1 AAV-based gene therapy prevents neuronal damage and degeneration, inhibits hippocampal atrophy, and reduces neuroinflammation in NHP AD models.”

    Animalsin NHP AD models with hippocampal hTau overexpressionbrain

    A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease-Like Non-Human Primate Model

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  4. AAV-NEUROD1 inhibits hippocampal atrophy in NHP AD models with hippocampal hTau overexpression.

    “NeuroD1 AAV-based gene therapy prevents neuronal damage and degeneration, inhibits hippocampal atrophy, and reduces neuroinflammation in NHP AD models.”

    Animalsin NHP AD models with hippocampal hTau overexpressionhippocampus

    A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease-Like Non-Human Primate Model

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

More on AAV-NEUROD1

Resveratrol

downmitochondrial content1downmitophagy1upNR1D11

1 study
  1. Resveratrol increases NR1D1 in non-human primates (consuming a high fat/sugar (HFS) diet) (∼1.5 and 3-fold increase).

    “A ∼1.5 and 3-fold increase in Rev-erb-α protein was detected in HFSR soleus and plantaris muscles compared to controls, respectively.”

    Animalsconsuming a high fat/sugar (HFS) dietsoleus and plantaris musclesup to 480 mg/day

    Resveratrol Blunts Mitochondrial Loss in Slow and Mixed Skeletal Muscle Phenotypes of Non-Human Primates following a Long-Term High Fat/Sugar Diet

    Journal of dietary supplements

  2. Resveratrol inhibits mitophagy in non-human primates (consuming a high fat/sugar (HFS) diet).

    “resveratrol appears to blunt mitochondrial losses with a high fat/sugar diet by tempering mito/autophagy rather than promoting mitochondrial biogenesis”

    Animalsconsuming a high fat/sugar (HFS) dietsoleus and plantaris musclesup to 480 mg/day

    Resveratrol Blunts Mitochondrial Loss in Slow and Mixed Skeletal Muscle Phenotypes of Non-Human Primates following a Long-Term High Fat/Sugar Diet

    Journal of dietary supplements

  3. Resveratrol prevents mitochondrial content in non-human primates (consuming a high fat/sugar (HFS) diet) (blunted ∼20-25% decrease).

    “there was a ∼20-25% decrease in mitochondrial content in HFS (n = 8) muscles as reflected in the COX2- and CYTB-to-GAPDH ratios using PCR analysis, which was blunted by resveratrol in HFSR”

    Animalsconsuming a high fat/sugar (HFS) dietsoleus and plantaris musclesup to 480 mg/day

    Resveratrol Blunts Mitochondrial Loss in Slow and Mixed Skeletal Muscle Phenotypes of Non-Human Primates following a Long-Term High Fat/Sugar Diet

    Journal of dietary supplements

More on Resveratrol

Raav/aβ

downamyloid plaque burden1upAβ oligomers1no changeinflammation1

1 study
  1. Raav/aβ showed no clear effect on inflammation in non-human primates (aged non-human primates).

    “without inflammatory or hemorrhagic changes in the brain”

    Animalsaged non-human primatesenteric-dissolving coated capsulesbrain

    An Oral Aβ Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Aβ Oligomers

    Journal of Alzheimer's disease : JAD

  2. Raav/aβ increases Aβ oligomers in non-human primates (aged non-human primates).

    “soluble Aβ and some Aβ oligomers were increased in rAAV-treated monkey brains”

    Animalsaged non-human primatesenteric-dissolving coated capsulesbrain

    An Oral Aβ Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Aβ Oligomers

    Journal of Alzheimer's disease : JAD

  3. Raav/aβ decreases amyloid plaque burden in non-human primates (aged non-human primates).

    “Pathological examinations of the brain showed significant reduction of the amyloid plaque burden and intracellular Aβ”

    Animalsaged non-human primatesenteric-dissolving coated capsulesbrain

    An Oral Aβ Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Aβ Oligomers

    Journal of Alzheimer's disease : JAD

More on Raav/aβ

GFD-CD3

downage-related pathologies1downsenescent cells1

1 study
  1. GFD-CD3 decreases age-related pathologies in non-human primates under transaminase-guided monitoring.

    “low-dose GFD-CD3 effectively eliminated senescent cells and alleviated age-related pathologies in aged mice and non-human primates without adverse effects”

    Animalsunder transaminase-guided monitoringlow dose

    Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates

    Aging cell

  2. GFD-CD3 decreases senescent cells in non-human primates under transaminase-guided monitoring.

    “low-dose GFD-CD3 effectively eliminated senescent cells and alleviated age-related pathologies in aged mice and non-human primates without adverse effects”

    Animalsunder transaminase-guided monitoringlow dose

    Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates

    Aging cell

More on GFD-CD3

VCAM-1-targeted nanoparticles

upgraft survival1downimmune cell adhesion1

1 study
  1. VCAM-1-targeted nanoparticles improve graft survival in non-human primates (porcine-to-primate cardiac xenotransplantation) (from 6.7 to 27.0 days (nearly fourfold)).

    “extends xenograft survival nearly fourfold, from 6.7 to 27.0 days.”

    Animalsporcine-to-primate cardiac xenotransplantation

    VCAM-1-targeting peptide assemblies protect vascular endothelium and prolong cardiac xenograft survival

    Science advances

  2. VCAM-1-targeted nanoparticles decrease immune cell adhesion in non-human primates (cardiac xenograft) (-73% (P < 0.001)).

    “VTN reduces immune cell adhesion by 73% (P < 0.001)”

    Animalscardiac xenograft

    VCAM-1-targeting peptide assemblies protect vascular endothelium and prolong cardiac xenograft survival

    Science advances

More on VCAM-1-targeted nanoparticles

QL9-21

downliver accumulation1upviral genome delivery to brain1

1 study
  1. QL9-21 decreases liver accumulation in non-human primates (2.6 fold reduction).

    “while concurrently reducing liver accumulation by 2.6 fold”

    Animalsliver

    LRP6-Guided Engineering of AAV9 Variants with Enhanced Blood-Brain Barrier Penetration and Reduced Liver Tropism in Non-Human Primates

    bioRxivPreprint

  2. QL9-21 increases viral genome delivery to brain in non-human primates (3-40 fold enhancement).

    “mediated a striking 3-40 fold enhancement in viral genome delivery across all examined brain regions versus AAV9”

    Animalsbrain

    LRP6-Guided Engineering of AAV9 Variants with Enhanced Blood-Brain Barrier Penetration and Reduced Liver Tropism in Non-Human Primates

    bioRxivPreprint

More on QL9-21

Focused ultrasound

upAAV delivery1uptransgene expression1

1 study
  1. Focused ultrasound increases transgene expression in non-human primates with focused ultrasound and intravenous microbubbles (up to 500-fold).

    “transgene expression up to 500-fold”

    Animalswith focused ultrasound and intravenous microbubblescaudate and putamen

    Focused ultrasound expands intra-CSF AAV delivery to deep brain regions in rats and non-human primates

    Molecular therapy : the journal of the American Society of Gene Therapy

  2. Focused ultrasound increases AAV delivery in non-human primates with focused ultrasound and intravenous microbubbles (up to 100-fold).

    “the AAV delivery to the caudate and putamen was increased up to 100-fold”

    Animalswith focused ultrasound and intravenous microbubblescaudate and putamen

    Focused ultrasound expands intra-CSF AAV delivery to deep brain regions in rats and non-human primates

    Molecular therapy : the journal of the American Society of Gene Therapy

More on Focused ultrasound

HMGB1 box a gene therapy

upcortical bone accumulation1downweight gain1

1 study
  1. HMGB1 box a gene therapy decreases weight gain in non-human primates.

    “Box A group trended to gain less weight than the PC group, without experiencing muscle loss.”

    Animalsplasmid56 weeksfemales

    Long-term Safety Pharmacology and Musculoskeletal Changes of HMGB1 Box A Gene Therapy in Middle-aged Monkeys

    In vivo (Athens, Greece)

  2. HMGB1 box a gene therapy increases cortical bone accumulation in non-human primates.

    “Box A promoted cortical bone accumulation in the tibial diaphysis.”

    Animalsplasmidbone56 weeksfemales

    Long-term Safety Pharmacology and Musculoskeletal Changes of HMGB1 Box A Gene Therapy in Middle-aged Monkeys

    In vivo (Athens, Greece)

More on HMGB1 box a gene therapy

All 33

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    In non-human primates, low-dose GFD-CD3 decreases senescent cells with transaminase-guided monitoring. Reviews of non-human primate research describe reduced graft rejection with xenotransplantation using multigene-modified pigs, associations between transcranial magnetic stimulation and network function, and improved vascular patency with induced pluripotent stem cells in allogeneic primate models.

  2. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 7Feb 2026: 6Mar 2026: 10Apr 2026: 2May 2026: 0Jun 2026: 2Jul 2026: 6Aug 2026: 4Sep 2026: 7Oct 2026: 6Nov 2026: 354 papers in 12 months
Acta Neuropathologica Communications

Peptide improved movement in mouse models of brain disease

Daily injections from 3 to 12 months of age improved movement and behavior in male and female mice modeling Huntington’s disease.Daily injections from 3 to 12 months of age improved movement and behavior in male and female mice modeling Huntington’s disease.

Mouse studyInterventions
NPJ Aging

Protein loss disrupts nuclear structure in primate cells

Restoring the protein’s activity restored nuclear structure and the ability to divide in cells from aged non-human primates and animals modeling a premature-aging…Restoring the protein’s activity restored nuclear structure and the ability to divide in cells from aged non-human primates and animals modeling a premature-aging disorder.

Animal cell studyMechanisms

See all 179 papers on non-human primates